Mild cognitive impairment: a concept in evolution.
Mild cognitive impairment: a concept in evolution.
复制标题
DOI：
10.1111/joim.12190
复制
发表时间：
2014-03
影响因子：
11.1
通讯作者：
Fratiglioni L
中科院分区：
文献类型：
--
作者：
Petersen RC;Caracciolo B;Brayne C;Gauthier S;Jelic V;Fratiglioni L
自2003年在关键研讨会上发表新的轻度认知障碍定义以来，轻度认知障碍（MCI）的结构在过去10年中不断发展，但核心标准保持不变。该结构已在全球范围内广泛用于临床和研究环境，以定义完整的认知功能和临床痴呆之间的灰色区域。关于MCI的发生、危险因素和进展的一组丰富的数据已经产生。研究之间的差异主要可以解释为标准的可操作性差异、标准应用的环境差异、受试者的选择以及纵向研究的随访时间长短。仍有待进一步探讨的主要争议问题是：算法与临床分类，临床判断的可靠性，认知表现的时间变化，以及推定的生物标志物的预测性。进一步发展MCI结构的一些建议包括针对特定人群和特定背景定制临床标准。将生物标志物添加到临床表型中是有希望的，但需要更深入的研究。将研究结果从专科诊所转化为人群环境，虽然具有挑战性，但将提高结局的一致性。需要进行更多的基于人群的认知老化和MCI的纵向研究来澄清所有这些问题。
The construct of mild cognitive impairment (MCI) has evolved over the past 10 years since the publication of the new MCI definition at the Key Symposium in 2003, but the core criteria have remained unchanged. The construct has been extensively used worldwide, both in clinical and research settings, to define the grey area between intact cognitive functioning and clinical dementia. A rich set of data regarding occurrence, risk factors, and progression of MCI has been generated. Discrepancies between studies can be mostly explained by differences in the operationalization of the criteria, differences in the setting where the criteria have been applied, selection of subjects, and length of follow-up in longitudinal studies. Major controversial issues that remain to be further explored are: algorithmic versus clinical classification, reliability of clinical judgment, temporal changes in cognitive performances, and predictivity of putative biomarkers. Some suggestions to further develop the MCI construct include the tailoring of the clinical criteria to specific populations and to specific contexts. The addition of biomarkers to the clinical phenotypes is promising but requires deeper investigation. Translation of findings from the specialty clinic to the population setting, although challenging, will enhance uniformity of outcomes. More longitudinal population-based studies on cognitive aging and MCI need to be performed to clarify all these issues.
登录
查看更多内容
影响因子：
2.8
作者：
Fennema-Notestine C;McEvoy LK;Hagler DJ Jr;Jacobson MW;Dale AM;The Alzheimer's Disease Neuroimaging Initiative
通讯作者：
The Alzheimer's Disease Neuroimaging Initiative
DOI：
10.3233/jad-122050
发表时间：
2013
期刊：
Journal of Alzheimer's disease : JAD
影响因子：
--
作者：
Caracciolo B;Gatz M;Xu W;Marengoni A;Pedersen NL;Fratiglioni L
通讯作者：
Fratiglioni L
影响因子：
7.2
作者：
Ganguli, Mary;Chang, Chung-Chou H.;Lee, Ching-Wen
通讯作者：
Lee, Ching-Wen
影响因子：
9.9
作者：
FLICKER, C;FERRIS, SH;REISBERG, B
通讯作者：
REISBERG, B
影响因子：
9.9
作者：
Busse, A.;Hensel, A.;Riedel-Heller, S. G.
通讯作者：
Riedel-Heller, S. G.